Adicet Expands CAR-T Portfolio With Cleared ADI-212 IND and In-Vivo Programs
Adicet disclosed FDA clearance of the ADI-212 IND for metastatic castration-resistant prostate cancer and unveiled an in-vivo CAR-T portfolio spanning multiple myeloma, non-Hodgkin lymphoma and solid tumors. ADI-212 is described as an off-the-shelf, gene-edited,…
